Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.

Next Previous
Trial Profile

Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2012

At a glance

  • Drugs Pioglitazone (Primary) ; Glibenclamide; Gliclazide; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms TOSCA-IT

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2012 Recruitment is expected to be complete by June 2013, according to an article published in Diabetes Care. At the time of publication, 2,400 patients had been randomized.
    • 01 Dec 2012 Planned number of patients changed from 5172 to 3371 according to an article published in Diabetes Care and the ClinicalTrials.gov registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top